QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
出版年份 2014 全文链接
标题
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 112, Issue 2, Pages 296-305
出版商
Springer Nature
发表日期
2014-10-29
DOI
10.1038/bjc.2014.564
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
- (2013) D. Y. C. Heng et al. ANNALS OF ONCOLOGY
- A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors
- (2013) Elisabeth I. Heath et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel
- (2013) Pierre Maison-Blanche et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
- (2013) John P. Crown et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy
- (2013) Jin Seok Ahn et al. LUNG CANCER
- Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents
- (2013) Steven J. Bowlin et al. MAYO CLINIC PROCEEDINGS
- Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)
- (2012) Jin Soo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
- (2012) Chiun Hsu et al. JOURNAL OF HEPATOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
- (2012) Sophie Leboulleux et al. LANCET ONCOLOGY
- 7051 POSTER Bicalutamide in Combination With Vandetanib or Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression – a Randomized, Double-blind Phase II Trial
- (2011) Y. Loriot et al. EUROPEAN JOURNAL OF CANCER
- Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Richard H. de Boer et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics
- (2011) Bruce A. Feinberg et al. MEDICAL ONCOLOGY
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
- (2010) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
- (2010) Yazdi K. Pithavala et al. INVESTIGATIONAL NEW DRUGS
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma
- (2010) Jerome Landry et al. JOURNAL OF SURGICAL ONCOLOGY
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- (2010) Roy S Herbst et al. LANCET ONCOLOGY
- Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine
- (2010) Sabrina Obers et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review
- (2009) Toni K. Choueiri et al. BJU INTERNATIONAL
- Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
- (2009) C. L. Bello et al. CLINICAL CANCER RESEARCH
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started